keratinocytes,"' fibroblasts, brain, various endocrine tissues and gastric mucosa.'0 It is at present unclear why only a proportion of patients with tumours that produce parathyroid hormone-related protein are hypercalcaemic, given the potent bone resorbing and calcium increasing effects of parathyroid hormone-related protein in vivo and in vitro." Various reasons have been suggested, including failure of parathyroid hormone-related protein translation from its messenger RNA,'4 low levels of protein secretion, low tumour mass,' concomitant secretion of other bone resorbing factors which act synergistically with parathyroid hormonerelated protein to cause hypercalcaemia,2' and the ability of homeostatic mechanisms to preserve normocalcaemia despite the release of the protein. ''4 To investigate further the association between the presence of parathyroid hormone-related protein in tumours and the development of hypercalcaemia, we carried out immunohistochemical staining for parathyroid hormone-related protein in a series of tumours from normocalcaemic and hypercalcaemic patients with cancer who also were evaluated biochemically for evidence of the protein's effects on bone and kidney.
To investigate further the association between the presence of parathyroid hormone-related protein in tumours and the development of hypercalcaemia, we carried out immunohistochemical staining for parathyroid hormone-related protein in a series of tumours from normocalcaemic and hypercalcaemic patients with cancer who also were evaluated biochemically for evidence of the protein's effects on bone and kidney.
Methods
Tumour tissue was available from 27 patients as the result of procedures performed during the course of routine management and provided that informed consent to participating in the study had been given. Eight patients were hypercalcaemic at the time of study (serum calcium adjusted for albumin of 2 70 mmol/l or greater) and 19 were normocalcaemic. Eleven of the patients who were initially normocalcaemic were subsequently followed up by regular checks of serum calcium until just before death; three of these patients developed hypercalcaemia and eight remained normocalcaemic. In the remaining eight normocalcaemic patients no further measurements of serum calcium were available, either because the patients were lost to follow up (n = 5), or because they died of early complications after surgical resection of lung tumours (n = 3; arrhythmia n = 1, pulmonary embolus n = 1; pneumonia n = 1).
Immunohistochemical staining for parathyroid hormone-related protein was performed on formalin fixed, paraffin wax embedded sections. The antiserum used for immunostaining was prepared in New Zealand white rabbits immunised against synthetic parathyroid hormone-related protein (1-34) as described previously.'2 This antiserum has been fully characterised in previous studies2 15 17 and is specific to the (1-34) portion of the parathyroid hormone-related protein molecule; it shows no cross reactivity with PTH or PTH-derived peptides in Western blots, or at high concentrations in blocking biological activity.
A positive control was included in every experiment consisting of a squamous carcinoma of the skin.'2 Standard negative controls for method and antibody were used as previously described,'2 '7 including alternating deletions of the antibody layers, primary antiserum, second antibody and peroxidaseantiperoxidase complex; and substitution of non-immune and unrelated immune rabbit serum for primary antiserum and preabsorption of the antibody overnight with parathyroid hormone-related protein (1-34) or PTH (1-34) peptides. All of these controls abolished staining, except for the overnight preabsorption with PTH (1-34) which had no effect.
In all patient samples the pattern of parathyroid hormone compared with 210-0 (52-2) cm' (range 654-523 6) in the hypercalcaemic patients (p < 0 02). In nine normocalcaemic patients whose tumours were excised there was no significant change in serum calcium values (before surgery mean (SEM) = 2 52 (0 01) mmol/l; after surgery 2 51 (0 01) mmol/l, p = NS). In contrast, serum calcium values fell significantly in five hypercalcaemic patients whose tumours were excised (before surgery = 3-02 (0 09) mmol/l; after surgery = 2 44 (0 03) mmol/l, p < 0 02). Table 2 shows the pattern of immunohistochemical staining for parathyroid hormonerelated protein in normocalcaemic and hypercalcaemic patients. All eight of the tumours from hypercalcaemic patients stained strongly positively for the protein. Of the 19 tumours from normocalcaemic patients, 11 (57%) stained strongly positive, six stained positive, and two negative (X2 = 4 78; p < 0 05). In the normocalcaemic patients there was no apparent relation between the pattern of parathyroid hormone-related protein staining and subsequent development of hypercalcaemia; in 11 patients where detailed follow up checks of serum calcium concentration were performed, three became hypercalcaemic (two negative tumours, one positive tumour) and eight remained normocalcaemic (four strongly positive, four positive). All three of the normocalcaemic patients who subsequently became hypercalcaemic had biochemical evidence of parathyroid hormone-related protein-mediated hypercalcaemia when serum calcium values increased; all were hypophosphataemic and one (with an initially negatively staining tumour) was also found to have reduced values oftubular reabsorption ofphosphate, raised values of tubular reabsorption of calcium, corrected for urinary sodium excretion, and very high cyclic AMP:creatinine concentrations.
Discussion
Biochemical evaluation of hypercalcaemic patients in this study showed features consistent with the actions of parathyroid hormonerelated protein on bone and kidney'; bone resorption, renal tubular reabsorption of calcium, and cyclic AMP excretion were all increased and serum phosphate and renal tubular reabsorption of phosphate reduced. These findings concur with previous clinical observations"' and, along with the demonstration of parathyroid hormone-related protein in tumour tissue by immunostaining, emphasise the importance of the protein as the predominant humoral mediator of hypercalcaemia in malignancy. '3 The increased cyclic AMP: creatinine values which we noted in four out of 19 (21%) normocalcaemic patients confirm the findings -4 L Example of strongly positive stainingfor parathyroid hormone-related protein in a squamous lung carcinoma from a hypercalcaemic patient. ,.,rsj, iti4. ,X ;
.- of previous workers25 and suggest that parathyroid hormone-related protein may also be released into the systemic circulation in normocalcaemic patients with cancer at concentrations which are presumably too low to cause a sustained increase in blood calcium activity. While measurement of plasma parathyroid hormone-related protein was not technically possible when our patients presented, it has been shown in a recent study that plasma concentrations may be increased in up to 25% of normocalcaemic cancer patients using a sensitive immunoradiometric assay.26
The present findings, together with previous immunohistochemical'2 and in situ hybridisation data,'4 show that parathyroid hormonerelated protein can be detected in tumours from both normocalcaemic and hypercalcaemic patients with cancer. Low tumour mass is an obvious explanation for the absence of hypercalcaemia in patients with positively staining tumours, and, indeed, tumour mass at the time of presentation was significantly lower in the normocalcaemic compared with the hypercalcaemic group. This is unlikely to have been the only factor in determining the occurrence of hypercalcaemia, however, as some normocalcaemic patients who exhibited positive or strongly positive staining for parathyroid hormone-related protein had tumours of equal size to those of the hypercalcaemic patients, and only one went on to develop hypercalcaemia despite progression of the tumours to a terminal stage.
Alternative explanations for the failure of such patients to develop hypercalcaemia include differences in the structure, biological effects, or rate of parathyroid hormone-related protein secretion between the normocalcaemic and hypercalcaemic subgroups. Several different types of parathyroid hormone-related protein with common amino terminal, but differing carboxyl-terminal, sequences may be generated as the result of differential splicing of the 3' end of the messenger RNA.'31327 Such differences may have existed in our patients, but would not have been detected by our antibody, in view of its amino-terminal specificity. While it is possible that these different forms of parathyroid hormone-related protein may have been processed in different ways or secreted at different rates, further studies on the molecular forms of the parathyroid hormone-related protein contained within the individual tumours, coupled with studies on intracellular processing and secretion of the peptide by cultured cell lines, would be needed to confirm whether this was the case. Although the possibility remains that the parathyroid hormone-related protein detected in tumour tissue from the normocalcaemic patients was not biologically active, this seems unlikely, given that the biological effects of parathyroid hormone-related protein (at least with regard to its renal tubular and bone resorbing effects) reside in the (1-34) portion of the molecule to which our antibody was directed.'À further explanation for differences in the degree of release of parathyroid hormonerelated protein by different tumours would be liberation of the protein from necrotic or ischaemic tissue. Such a mechanism is difficult to confirm or exclude, although with careful examination of excised tumour specimens and the histological sections used for immunohistochemistry, there seemed to be no difference in the degree of necrosis in tumours from normocalcaemic compared with hypercalcaemic patients.
The absence of parathyroid hormone-related protein in two squamous cell tumours from patients who subsequently developed biochemical evidence of mediated hypercalcaemia is puzzling, as we have previously reported identification of cytoplasmic parathyroid hormone-related protein in normal skin and in 100% of a series of squamous carcinomas from normocalcaemic patients. 2 This most probably relates to technical factors such as loss of the antigen during fixation, although expression of parathyroid hormone-related protein in these patients at a later stage in tumour development, or selective parathyroid hormone-related protein expression in some but not all areas of tumour tissue, would also be possible. Unfortunately, however, we were unable to obtain further tissue in either case to investigate these possibilities.
